Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences (NASDAQ: TLSA; LSE: TILS) announced that CEO Dr. Kunwar Shailubhai will appear on The RedChip Money Report airing on Bloomberg Television. The interview is set for February 27, 2021, at 7 p.m. EST in the U.S., and February 28, 2021, at 6 p.m. CET in Europe. Dr. Shailubhai will discuss topline data from the COVID-19 trial and upcoming Phase 2 trials for innovative therapeutics, including Foralumab, targeting various autoimmune diseases.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced its participation in the BIO CEO & Investor Digital Conference from February 16-18, 2021. CEO Dr. Kunwar Shailubhai emphasized the company's focus on innovative therapeutics, highlighting topline data from a recent COVID-19 trial and upcoming Phase 2 trials in 2021. Tiziana is advancing its monoclonal antibody Foralumab for multiple autoimmune diseases and is accelerating the development of an anti-IL6 receptor antibody, important for treating inflammation related to various conditions.
Tiziana Life Sciences plc (NASDAQ: TLSA) has appointed Dr. Thomas Adams as the new executive director and Head of Drug Development. With a Ph.D. in Biochemistry, Dr. Adams brings extensive experience from roles at Cardiff Oncology and Hepion Pharmaceuticals. His leadership is expected to enhance the development of Tiziana's oncology programs, including Milciclib and Foralumab, which target various cancers and inflammatory diseases. The Company aims to leverage his background in precision medicine to accelerate therapeutic advancements. Notably, Dr. Adams previously faced involvement in Synergy Pharmaceuticals, which filed for bankruptcy in 2018.
Tiziana Life Sciences (NASDAQ:TLSA) announced an interview with CEO Dr. Kunwar Shailubhai discussing the therapeutic potential of Foralumab for COVID-19. The nasal administration of Foralumab demonstrated nearly double the improvement in lung CT scans compared to a control group. This proprietary nasal delivery aims to modulate immunity and alleviate symptoms, especially with emerging COVID-19 variants in the UK, South Africa, and Brazil. Tiziana is also developing Foralumab for liver diseases and has ongoing projects targeting various autoimmune conditions.
On January 27, 2021, Tiziana Life Sciences (Nasdaq: TLSA) announced the filing of a "universal" shelf registration statement with the SEC for up to $250 million in securities. This move allows for efficient access to U.S. capital markets. The registration includes a preliminary prospectus for an "at-the-market" sales agreement with B. Riley Securities, enabling the potential sale of up to $100 million in American Depositary Shares. Notably, Tiziana has no immediate plans for any offerings under this registration.
Tiziana Life Sciences announced that its CEO and CSO, Dr. Kunwar Shailubhai, will host a fireside chat on January 21, 2021, at 3 PM ET / 8 PM GMT. The discussion will provide updates on the company's ongoing developments, particularly in oncology and inflammation. Tiziana is advancing therapeutics such as Foralumab, a fully human anti-CD3 monoclonal antibody, and its IL6R monoclonal antibody for treating COVID-19. Interested parties can join the webcast through a provided link.
Tiziana Life Sciences has announced its transition from AIM to the Main Market of the London Stock Exchange, effective January 21, 2021. Following the last trading day on AIM on January 20, the Company’s Ordinary Shares will be admitted to the Official List and commence trading on the Main Market. Tiziana focuses on developing innovative treatments for oncology, inflammation, and infectious diseases, with ongoing Phase 2 studies for its uniquely human anti-CD3 monoclonal antibody, Foralumab, targeting conditions such as Crohn's Disease and multiple sclerosis.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the appointment of Dr. Neil Graham as Chief Medical Officer. Dr. Graham has extensive experience in medicines development, having previously held roles at Regeneron and Vertex. He played a key role in the launch of blockbuster drugs like Dupixent. Tiziana's unique monoclonal antibody platform for autoimmune diseases could significantly impact the treatment landscape. The company is advancing clinical studies for Foralumab, an innovative monoclonal antibody addressing various autoimmune conditions.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced its participation in the J.P. Morgan 39th Annual Healthcare Conference 2021. CEO Dr. Kunwar Shailubhai expressed excitement about presenting significant advancements, including topline data from a COVID-19 trial expected this month and anticipated launches of multiple Phase 2 trials in 2021. The company is exploring Foralumab, a fully human anti-CD3 monoclonal antibody, for various autoimmune diseases and aims to address IL6-induced inflammation in COVID-19 patients. For more details, visit Tiziana's website.
Tiziana Life Sciences (NASDAQ: TLSA) announced its participation in Biotech Showcase 2021, providing on-demand presentations for attendees. Dr. Kunwar Shailubhai, CEO, stated that topline data from a COVID-19 trial is expected this month, with several Phase 2 trial launches planned for 2021. With the potential application of Foralumab in various autoimmune diseases, the company aims to achieve significant milestones impacting its valuation. Biotech Showcase serves as a networking platform for life science professionals and investors, promoting innovations in drug discovery.